Trial · NCT02638766
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
NCT02638766, Phase 2, Completed, Grupo Espanol de Investigacion en Sarcomas
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST. Trials, record NCT02638766. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02638766
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
- NCT number
- NCT02638766
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- regorafenib
- First posted
- 2015-12-23
- Last updated
- 2023-03-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Control Rate | every 8 weeks during 36 months | the sum of complete responses (CR) + partial responses (PR) + stable disease (SD). |
| Secondary | Progression free survival | every 8 weeks during 36 months | Number of months without progression |
| Secondary | Overall survival | Every 8 weeks during 36 months | Number of months alive |
| Secondary | Responses determined by CHOI | every 8 weeks during 36 months | Measure tumor size |
| Secondary | Correlation with translational research | After 36 months of recruitment | Relation between the clinical data obtained and the data obtained from translational research |
| Secondary | Safety (adverse events following CTCAE v4.03) | Every 28 days until 30 days after last dose | Evaluation of adverse events following CTCAE v4.03 |
| Secondary | Early metabolic response by PET scan | After 1 month of starting treatment | Evaluation of metabolic response to treatment |
| Secondary | Quality of life by EORCT QLQ C30 questionnaire | Day 1 of each cycle. Pre-treatment administration | EORCT QLQ C30 questionnaires |
| Secondary | Quality of life by EQ-ED-5L questionnaire | Day 1 of each cycle. Pre-treatment administration | EQ-ED-5L questionnaires |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37559050 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02638766
GET https://conductscience.org/api/trials/v1/NCT02638766/registered